Patents by Inventor Chifumi Imai
Chifumi Imai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240059795Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.Type: ApplicationFiled: October 27, 2023Publication date: February 22, 2024Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi
-
Publication number: 20230210991Abstract: In one non-limiting embodiment, the present disclosure is an antibody-containing formulation comprising an anti-IL-6 receptor antibody as an active ingredient, and contains histidine-aspartate buffer or histidine-glutamate buffer, Poloxamer 188, and arginine, and has a pH of 5.5 to 6.6. In one non-limiting embodiment, the present disclosure is a method of stabilizing an antibody-containing solution, a method of suppressing antibody association (e.g., dimerization), and a method of suppressing the generation of insoluble particles, wherein L-aspartic acid or L-glutamic acid, and optionally, Poloxamer 188 are added.Type: ApplicationFiled: May 28, 2021Publication date: July 6, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Daisuke Kameoka, Masaya Yasutake, Masakazu Fukuda, Atsushi Watanabe, Tomoyuki Igawa, Chifumi Imai, Akira Hayasaka
-
Publication number: 20230212315Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.Type: ApplicationFiled: December 15, 2022Publication date: July 6, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi
-
Publication number: 20220267470Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor DC/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.Type: ApplicationFiled: April 26, 2022Publication date: August 25, 2022Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi
-
Publication number: 20210189006Abstract: The present invention relates to stable antibody-containing solution formulations in which aggregate formation of Emicizumab (ACE910) which is a bispecific antibody functionally substituting for FVIII, is suppressed. Specifically, the present invention relates to the above-mentioned antibody-containing solution formulations of pH 4.5 to 6.5 that contain the aforementioned bispecific antibody at 20 to 180 mg/mL, 10 mM to 40 mM histidine-aspartate buffer, Poloxamer 188 at 0.2 to 1 mg/mL, and 100 mM to 300 mM arginine.Type: ApplicationFiled: April 27, 2017Publication date: June 24, 2021Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Atsushi SAEKI, Shaw NISHIZAWA, Hitoshi SASAKI, Chifumi IMAI, Tomoyuki IGAWA
-
Patent number: 10450381Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.Type: GrantFiled: April 19, 2016Date of Patent: October 22, 2019Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi
-
Publication number: 20190315884Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.Type: ApplicationFiled: July 2, 2019Publication date: October 17, 2019Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi
-
Publication number: 20170022293Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.Type: ApplicationFiled: October 7, 2016Publication date: January 26, 2017Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi
-
Publication number: 20160222129Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.Type: ApplicationFiled: April 19, 2016Publication date: August 4, 2016Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi
-
Patent number: 9334331Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.Type: GrantFiled: November 17, 2011Date of Patent: May 10, 2016Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi
-
Publication number: 20140370018Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.Type: ApplicationFiled: September 5, 2013Publication date: December 18, 2014Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi
-
Publication number: 20140037632Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.Type: ApplicationFiled: September 6, 2013Publication date: February 6, 2014Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi
-
Publication number: 20130330345Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.Type: ApplicationFiled: November 17, 2011Publication date: December 12, 2013Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi